Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 24;9(11):e031186.
doi: 10.1136/bmjopen-2019-031186.

Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis

Y Jiang  1 , Weiyi Ni  2 , Jing Wu  3
Affiliations

Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis

Y Jiang et al. BMJ Open. .

Abstract

Objectives: To evaluate the cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine for the prevention of cervical cancer in China.

Design: Health economic modelling using the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model populated with China-specific data.

Setting: Individual cervical cancer prevention in China using the 9-valent HPV vaccine from the perspective of private sector purchasers in relation to receiving other HPV vaccines and not receiving vaccination for 16-year-old girls in China who had not been previously infected with HPV.

Participants: Not applicable.

Interventions: Vaccination using the 9-valent, the quadrivalent and the bivalent vaccines.

Primary outcome measure: Incremental costs per disability-adjusted life year (DALY) prevented.

Results: In the base case, the incremental costs per DALY prevented were, respectively, US$35 000 and US$50 455 compared with the quadrivalent and the bivalent vaccines, both of which were above the cost-effective threshold of US$25 920/DALY prevented. To be cost-effective in these comparisons, the 9-valent vaccine should be priced at $550 and $450 for the full doses, respectively. To be highly cost-effective, the price thresholds were $435 and $335. The incremental costs per DALY prevented in relation to no vaccination was US$23 012, making the 9-valent vaccine marginally cost-effective. The results were robust in most one-way sensitivity analyses including changing vaccination age to 13 and 26 years.

Conclusions: At the current price, the 9-valent HPV vaccine is not cost-effective compared with the quadrivalent and the bivalent vaccines for young girls in China who had not been previously infected with HPV. Policymakers and clinicians should keep potential vaccine recipients informed about the economic profile of the 9-valent vaccine and carefully consider expanding its use in China at the current price.

Keywords: China; HPV; cervical neoplasia; cost-effectiveness; vaccination.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Liu A. 9 days for Gardasil 9: China hands out landmark NOD with lightning speed, 2018. Available: https://www.fiercepharma.com/pharma-asia/9-days-for-gardasil-9-china-han...
    1. HPV vaccine becomes available in China for women between 16 to 26 years old, 2018. Available: https://www.firstwordpharma.com/node/1560878?tsid=6
    1. Chesson HW, Markowitz LE, Hariri S, et al. . The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Hum Vaccin Immunother 2016;12:1363–72. 10.1080/21645515.2016.1140288 - DOI - PMC - PubMed
    1. Levin CE, Sharma M, Olson Z, et al. . An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine 2015;33:2830–41. 10.1016/j.vaccine.2015.02.052 - DOI - PubMed
    1. Canfell K, Shi J-F, Lew J-B, et al. . Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 2011;29:2487–94. 10.1016/j.vaccine.2010.12.085 - DOI - PubMed

MeSH terms

Substances